Literature DB >> 11927616

GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes.

Vissia Viglietta1, Sally C Kent, Tihamer Orban, David A Hafler.   

Abstract

Insulin-dependent type 1 diabetes is an autoimmune disease mediated by T lymphocytes recognizing pancreatic islet cell antigens. Glutamic acid decarboxylase 65 (GAD65) appears to be an important autoantigen in the disease. However, T cells from both patients with type 1 diabetes and healthy subjects vigorously proliferate in response to GAD65 stimulation ex vivo, leading us to postulate that the critical event in the onset of human diabetes is the activation of autoreactive T cells. Thus, we investigated whether GAD65-reactive T cells in patients with diabetes functioned as previously activated memory T cells, no longer requiring a second, costimulatory signal for clonal expansion. We found that in patients with new-onset type 1 diabetes, GAD65-reactive T cells were strikingly less dependent on CD28 and B7-1 costimulation to enter into cell cycle and proliferate than were equivalent cells derived from healthy controls. We hypothesize that these autoreactive T cells have been activated in vivo and have differentiated into memory cells, suggesting a pathogenic role in type 1 diabetes. In addition, we observed different effects with selective blockade of either B7-1 or B7-2 molecules; B7-1 appears to deliver a negative signal by engaging CTLA-4, while B7-2 engagement of CD28 upregulates T cell proliferation and cytokine secretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927616      PMCID: PMC150925          DOI: 10.1172/JCI14114

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

Review 1.  New perspectives of CD28-B7-mediated T cell costimulation.

Authors:  J A Bluestone
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Expression and functional significance of an additional ligand for CTLA-4.

Authors:  D J Lenschow; G H Su; L A Zuckerman; N Nabavi; C L Jellis; G S Gray; J Miller; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

4.  T helper cell subsets in insulin-dependent diabetes.

Authors:  J D Katz; C Benoist; D Mathis
Journal:  Science       Date:  1995-05-26       Impact factor: 47.728

5.  Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.

Authors:  A H Cross; T J Girard; K S Giacoletto; R J Evans; R M Keeling; R F Lin; J L Trotter; R W Karr
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.

Authors:  M Croft; L M Bradley; S L Swain
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

7.  Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.

Authors:  P J Perrin; D Scott; L Quigley; P S Albert; O Feder; G S Gray; R Abe; C H June; M K Racke
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

8.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

9.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  70 in total

Review 1.  Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes.

Authors:  Ake Lernmark
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 3.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 4.  Immune pathophysiology of aplastic anemia.

Authors:  Shinji Nakao; Xingmin Feng; Chiharu Sugimori
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

5.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

6.  Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Authors:  Philippe Azam; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Stephen Griffey; Heike Wulff
Journal:  J Invest Dermatol       Date:  2007-02-01       Impact factor: 8.551

7.  Immunomodulation of the anti-islet CD8 T cell response by B7-2.

Authors:  Deepak Yadav; Nora Sarvetnick
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

8.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes.

Authors:  Li Zhang; Frances Crawford; Liping Yu; Aaron Michels; Maki Nakayama; Howard W Davidson; John W Kappler; George S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.